Stephenson Harwood has won a lead role on an India outbound investment healthcare deal worth an estimated $1.5bn (£934m).

The deal will see acquisitive Mumbai-listed healthcare company Piramal Healthcare buy worldwide rights to Bayer’s molecular imaging products, including a pioneering method to diagnose Alzheimer’s disease at an early stage.